Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Maria Esposito

Showing results (241-250 of 284) with videos related to

Pageof 29
Sort By:
Blood Advances|April 22, 2026
Clinical variability of ATP11C-related hemolytic anemia: expanding the phenotypic and diagnostic spectrumVanessa D'Onofrio, Federica Maria Esposito, Roberta Marra, et al.
Journal of Neurology|October 19, 2014
Long-term outcome of epilepsy in patients with Prader-Willi syndromeAlberto Verrotti, Raffaella Cusmai, Daniela Laino, et al.
The Journal of Dermatological Treatment|October 27, 2024
Effectiveness of tildrakizumab 200 mg: an Italian multicenter studyAnnunziata Dattola, Nicoletta Bernardini, Francesca Svara, et al.
Dermatology and Therapy|January 23, 2025
Real-Life Experience with Tildrakizumab in Plaque Psoriasis with Palmoplantar Involvement: A Multi-Center Retrospective Italian StudyFederico Diotallevi, Maria Esposito, Maria Concetta Fargnoli, et al.
Psoriasis (Auckland, N.Z.)|September 22, 2025
Long-Term Real-World Effectiveness and Drug Survival of Guselkumab in Patients with Psoriasis: A 5-Year Retrospective StudyEdoardo Mortato, Marina Talamonti, Lorenzo Marcelli, et al.
Expert Opinion on Biological Therapy|June 16, 2022
Real-world outcomes in patients with moderate-to-severe plaque psoriasis treated with guselkumab for up to 1 yearMarco Galluzzo, Marina Talamonti, Nicoletta Bernardini, et al.
Molecular Psychiatry|March 24, 2026
Interventions for negative symptoms in schizophrenia: efficacy and clinical interpretability in a meta-analysis of 451 randomized controlled trialsStefano Damiani, Riccardo Stefanelli, Lydia Fortea, et al.
Dermatology and Therapy|April 16, 2025
Predictive Factors for Super Responder Status and Long-Term Effectiveness of Guselkumab in Psoriasis: A Multicenter Retrospective StudyEdoardo Mortato, Marina Talamonti, Lorenzo Marcelli, et al.
Clinical and Experimental Dermatology|April 16, 2025
A Long-Term Real-Life Safety Study of Guselkumab in Psoriasis Patients with Infectious Comorbidities, Malignancies or Heart Disease: The EARLY StudyEdoardo Mortato, Marina Talamonti, Lorenzo Marcelli, et al.
European Journal of Paediatric Neurology : EJPN : Official Journal of the European Paediatric Neurology Society|August 5, 2015
Refractory absence seizures: An Italian multicenter retrospective studyEmilio Franzoni, Sara Matricardi, Veronica Di Pisa, et al.
Pageof 29

Showing results (241-250 of 284) with videos related to

Sort By:
Pageof 29
Blood Advances|April 22, 2026
Clinical variability of ATP11C-related hemolytic anemia: expanding the phenotypic and diagnostic spectrumVanessa D'Onofrio, Federica Maria Esposito, Roberta Marra, et al.
Journal of Neurology|October 19, 2014
Long-term outcome of epilepsy in patients with Prader-Willi syndromeAlberto Verrotti, Raffaella Cusmai, Daniela Laino, et al.
The Journal of Dermatological Treatment|October 27, 2024
Effectiveness of tildrakizumab 200 mg: an Italian multicenter studyAnnunziata Dattola, Nicoletta Bernardini, Francesca Svara, et al.
Dermatology and Therapy|January 23, 2025
Real-Life Experience with Tildrakizumab in Plaque Psoriasis with Palmoplantar Involvement: A Multi-Center Retrospective Italian StudyFederico Diotallevi, Maria Esposito, Maria Concetta Fargnoli, et al.
Psoriasis (Auckland, N.Z.)|September 22, 2025
Long-Term Real-World Effectiveness and Drug Survival of Guselkumab in Patients with Psoriasis: A 5-Year Retrospective StudyEdoardo Mortato, Marina Talamonti, Lorenzo Marcelli, et al.
Expert Opinion on Biological Therapy|June 16, 2022
Real-world outcomes in patients with moderate-to-severe plaque psoriasis treated with guselkumab for up to 1 yearMarco Galluzzo, Marina Talamonti, Nicoletta Bernardini, et al.
Molecular Psychiatry|March 24, 2026
Interventions for negative symptoms in schizophrenia: efficacy and clinical interpretability in a meta-analysis of 451 randomized controlled trialsStefano Damiani, Riccardo Stefanelli, Lydia Fortea, et al.
Dermatology and Therapy|April 16, 2025
Predictive Factors for Super Responder Status and Long-Term Effectiveness of Guselkumab in Psoriasis: A Multicenter Retrospective StudyEdoardo Mortato, Marina Talamonti, Lorenzo Marcelli, et al.
Clinical and Experimental Dermatology|April 16, 2025
A Long-Term Real-Life Safety Study of Guselkumab in Psoriasis Patients with Infectious Comorbidities, Malignancies or Heart Disease: The EARLY StudyEdoardo Mortato, Marina Talamonti, Lorenzo Marcelli, et al.
European Journal of Paediatric Neurology : EJPN : Official Journal of the European Paediatric Neurology Society|August 5, 2015
Refractory absence seizures: An Italian multicenter retrospective studyEmilio Franzoni, Sara Matricardi, Veronica Di Pisa, et al.
Pageof 29